Circadia Health develops predictive monitoring tools for post-acute care settings, combining radar-based hardware, artificial intelligence, and software. The company's approach centers on contactless technology designed to capture patient vital signs without physical contact, a method intended to enable continuous oversight while reducing clinical burden. Its product line includes the FDA-cleared C200 device, which uses radar to monitor patients, and a Clinical Intelligence Platform that translates monitoring data into clinical insights.
The company's stated aim is to reduce rehospitalizations and improve patient outcomes in post-acute care. According to the company, its Circadia Platform currently supports the monitoring of over 30,000 patients daily, and facilities using the system have seen a 30% reduction in rehospitalizations after 12 months of deployment.
Circadia Health's technical work spans AI, hardware engineering, software development, and predictive analytics, with a specific focus on radar technology for medical applications. The company positions itself as working to establish new standards of care in an area of healthcare where early detection of patient deterioration can significantly affect outcomes.
